DESCRIPTION

Hematology Oncology and Stem Cell Therapy is an international, peer-reviewed, open access journal that provides a vehicle for publications of high-quality clinical as well as basic science research reports in hematology and oncology. The contents of the journal also emphasize the growing importance of hematopoietic stem cell therapy for treatment of various benign and malignant hematologic disorders and certain solid tumors. The journal prioritizes publication of original research articles but also would give consideration for brief reports, review articles and special communications. It also offers a special section for clinically relevant images that provide an important educational value.

ABSTRACTING AND INDEXING

Directory of Open Access Journals (DOAJ)
PubMed/Medline
Scopus

EDITORIAL BOARD

**Editor-in-Chief**

Mahmoud Aljurf, Director, Adult HSCT Program; Deputy Director, Oncology Center; Scientific Director EMBMT; King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
Areas of expertise - Leukemia, Lymphoma, Bone Marrow Failure

**Associate Editors**

Mohamed A. Kharfan-Dabaja, Mayo Clinic, Dept. of Hematology-Oncology, Blood and Marrow Transplantation Program, Jacksonville, Florida, United States of America
Areas of expertise - Immuno-Oncology, Stem Cell Transplantation

Ghassan Abou-Alfa, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
Areas of expertise - Gastrointestinal Oncology

Mohammad Al Shabanah, King Faisal Specialist Hospital and Research Centre Radiation Oncology Research Unit, Riyadh, Saudi Arabia
Areas of expertise - Breast Cancer, Radiation Oncology
**Associate Editor for Hematologic Malignancies and Non Neoplastic Hematology**
Usama Gergis, Weill Cornell Medicine, Hematology and Oncology, Leukemia & Bone Marrow Transplant Service, New York, United States of America
Areas of expertise - Stem Cell Transplantation

**Associate Editor for Lymphoma, Myeloma, Cellular Therapies and Stem cell Transplantation**
Mehdi Hamadani, Medical College of Wisconsin, Milwaukee, Wisconsin, United States of America
Areas of expertise - Lymphoid Malignancies

**Associate Editor for Cellular Therapy and Hematopoietic Stem Cell Transplantation**
Navneet Majhail, Cleveland Clinic, Cleveland, Ohio, United States of America
Areas of expertise - Stem Cell Transplantation, Hematologic Malignancies

**Associate Editor for Solid Tumors**
Lubna N. Chaudhary, Medical College of Wisconsin Division of Hematology and Oncology, Milwaukee, United States of America
Areas of expertise - Breast cancer tumor biology, Endocrine resistance mechanisms, Breast cancer developmental therapeutics

**Editorial Board**
Abdalla Awadi Abbadi, The University of Jordan School of Medicine, Amman, Jordan
Areas of expertise - Hematologic Malignancies

Hikmat Abdel-Razeq, King Hussein Cancer Center, Amman, Jordan
Areas of expertise - Breast Cancer, Adult Solid Tumors

Mohammad Al Shabanah, King Faisal Specialist Hospital and Research Centre Radiation Oncology Research Unit, Riyadh, Saudi Arabia
Areas of expertise - Breast Cancer, Radiation Oncology

Hazaa Al Zahra, King Faisal Specialist Hospital and Research Centre Adult Hematology HSCT Section, Riyadh, Saudi Arabia
Areas of expertise - Hemostasis and Thrombosis, Bone Marrow Failure

Abdulaziz Albadawi, King Faisal Specialist Hospital and Research Centre Department of Obstetrics and Gynecology, Riyadh, Saudi Arabia
Areas of expertise - Gynecologic Oncology

Bassim Albeirouti, King Faisal Specialist Hospital and Research Centre - Jeddah, Jeddah, Saudi Arabia
Areas of expertise - Hematologic Malignancies

Kamran Alimoghaddam, Shariati Hospital, Tehran, Iran
Areas of expertise - Hematologic Malignancies

Amani Alkofide, King Faisal Specialist Hospital and Research Centre Adult Hematology HSCT Section, Riyadh, Saudi Arabia
Areas of expertise - Pediatric Oncology, Pediatric Solid Tumors

Fahad Almahre, King Faisal Specialist Hospital and Research Centre Adult Hematology HSCT Section, Riyadh, Saudi Arabia
Areas of expertise - Hemoglobin Disorders

Ahmed Alsaeed, King Saud Bin Abdulaziz University for Health Sciences, Adult Hematology / Bone Marrow Transplantation, Riyadh, Saudi Arabia
Areas of expertise - Hematologic Malignancies

Mutlu Arat, Istanbul Florence Nightingale Hospital, Istanbul, Turkey
Areas of expertise - Gastrointestinal and Genito-urinary Oncology

Mohamed Amine Bekadja, The Algerian society of Hematology and Blood Transfusion, Department of Cell Therapy and Hematology, Oran, Algeria
Areas of expertise - Multiple Myeloma, Adult Stem Cell Transplantation

Carlos Sergio Chiattone, Faculty of Medical Sciences of Santa Casa of Sao Paulo Department of Hematology, Sao Paulo, Brazil
Areas of expertise - Hematologic Malignancies

Said Dermime, King Fahad Specialist Hospital, Department of Biomedical Research, Dammam, Saudi Arabia
Areas of expertise - Immuno-Oncology, Tumor Vaccines
**Riad El Fakih**, Alfaisal University, Riyadh, Saudi Arabia
Bone marrow transplant, stem cell transplant, lymphoma, CAR-T cell

**Asma El Quessar**, Ibn Rochd University Hospital Center Department of Oncology-Hematology, Casablanca, Morocco

**Hassan El Solh**, King Faisal Specialist Hospital and Research Centre Oncology Centre, Riyadh, Saudi Arabia
Bone marrow transplant, stem cell transplant, lymphoma, CAR-T cell

**Tusneem Elhassan**, King Faisal Specialist Hospital and Research Centre Oncology Centre, Riyadh, Saudi Arabia
Areas of expertise - Clinical Trials Design, Statistics

**David Gómez Almaguer**, Autonomous University of Nuevo Leon, San Nicolas De Los Garza, Mexico
Areas of expertise - Pediatric Oncology, Pediatric Stem Cell Transplantation

**Hassan El Solh**, King Faisal Specialist Hospital and Research Centre Oncology Centre, Riyadh, Saudi Arabia
Bone marrow transplant, stem cell transplant, lymphoma, CAR-T cell

**Asma El Quessar**, Ibn Rochd University Hospital Center Department of Oncology-Hematology, Casablanca, Morocco

**Hassan El Solh**, King Faisal Specialist Hospital and Research Centre Oncology Centre, Riyadh, Saudi Arabia
Bone marrow transplant, stem cell transplant, lymphoma, CAR-T cell

**Tusneem Elhassan**, King Faisal Specialist Hospital and Research Centre Oncology Centre, Riyadh, Saudi Arabia
Areas of expertise - Clinical Trials Design, Statistics

**David Gómez Almaguer**, Autonomous University of Nuevo Leon, San Nicolas De Los Garza, Mexico
Areas of expertise - Pediatric Oncology, Pediatric Stem Cell Transplantation

**Amir Ali Hamidieh**, Tehran University of Medical Sciences Pediatric Cell Therapy Research Center, Tehran, Iran
Areas of expertise - Pediatric Stem Cell Transplantation

**Shakrukh K. Hashmi**, Sheikh Shakhbout Medical City, Abu Dhabi, United Arab Emirates
Areas of expertise - Cancer Late Effects, Stem Cell Transplantation

**Yasser Khafaga**, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
Areas of expertise - Pediatric Solid Tumors, Radiation Oncology

**Yoshihisa Kodera**, Aichi Medical University Graduate School of Medicine School of Medicine, Aichi-Gun, Japan
Areas of expertise - Pediatric Stem Cell Transplantation

**Mickey Koh**, Singapore General Hospital Department of Haematology, Singapore, Singapore
Areas of expertise - Stem Cell Transplantation, Cellular Therapy

**Saleh Ladeb**, National Center for Bone Marrow Transplantation Department of Hematology, Tunis, Tunisia
Areas of expertise - Stem Cell Transplantation

**Jong-Wook Lee**, Catholic University of Korea School of Medicine Department of Internal Medicine, Seoul, South Korea
Areas of expertise - Stem Cell Transplantation, Hematologic Malignancies

**Dao-Pei Lu**, Hebei Yanda Lu Daopei Hospital, Beijing, China
Areas of expertise - CAR-T Cell Therapy

**Hossam Kamel Mahmoud**, Cairo University National Cancer Institute Department of Medical Oncology, Cairo, Egypt
Areas of expertise - Stem Cell Transplantation

**Tarek Ben Othman**, National Center for Bone Marrow Transplantation Department of Hematology, Tunis, Tunisia
Areas of expertise - Stem Cell Transplantation

**Moosa Patel**, University of the Witwatersrand Johannesburg School of Clinical Medicine, Johannesburg, South Africa
Areas of expertise - Hematologic Malignancies

**Guillermo Ruiz-Arguelles**, Haematology and Internal Medicine Centre, Monterrey, Mexico
Areas of expertise - Hematologic Malignancies

**Alok Srivastava**, The Tamil Nadu Dr. M.G.R. Medical University, Department of Hematology, Chennai, India
Areas of expertise - Stem Cell Transplantation, Hematologic Malignancies

**Publication office staff**

**Amal Al-Ghammas**

**Reina Tejano**

**Janelle Vales**
GUIDE FOR AUTHORS

INTRODUCTION
The Editors of Hematology/Oncology and Stem Cell Therapy welcome contributions from our readers. We seek high quality clinical and basic research reports in hematology and oncology, including the use of stem cell therapy in treating hematologic diseases and malignancies, from throughout the world, but particularly from countries whose research might be underrepresented in the current medical literature. Priority will be given to manuscripts that have a greater public health impact or that highlight unique geographic distributions or behaviors of blood diseases or cancer. We publish original research reports, brief communications, reviews, editorials, special communications and letters.

Submission checklist
You can use this list to carry out a final check of your submission before you send it to the journal for review. Please check the relevant section in this Guide for Authors for more details.

Ensure that the following items are present:

One author has been designated as the corresponding author with contact details:
• E-mail address
• Full postal address

All necessary files have been uploaded:
Manuscript:
• Include keywords
• All figures (include relevant captions)
• All tables (including titles, description, footnotes)
• Ensure all figure and table citations in the text match the files provided
• Indicate clearly if color should be used for any figures in print
Graphical Abstracts / Highlights files (where applicable)
Supplemental files (where applicable)

Further considerations
• Manuscript has been 'spell checked' and 'grammar checked'
• All references mentioned in the Reference List are cited in the text, and vice versa
• Permission has been obtained for use of copyrighted material from other sources (including the Internet)
• A competing interests statement is provided, even if the authors have no competing interests to declare
• Journal policies detailed in this guide have been reviewed
• Referee suggestions and contact details provided, based on journal requirements

For further information, visit our Support Center.

BEFORE YOU BEGIN

Ethics in publishing
Please see our information on Ethics in publishing.

Studies in humans and animals
If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. The manuscript should be in line with the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals and aim for the inclusion of representative human populations (sex, age and ethnicity) as per those recommendations. The terms sex and gender should be used correctly.

Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.
All animal experiments should comply with the ARRIVE guidelines and should be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, EU Directive 2010/63/EU for animal experiments, or the National Research Council's Guide for the Care and Use of Laboratory Animals and the authors should clearly indicate in the manuscript that such guidelines have been followed. The sex of animals must be indicated, and where appropriate, the influence (or association) of sex on the results of the study.

**Informed consent and patient details**

Studies on patients or volunteers require ethics committee approval and informed consent, which should be documented in the paper. Appropriate consents, permissions and releases must be obtained where an author wishes to include case details or other personal information or images of patients and any other individuals in an Elsevier publication. Written consents must be retained by the author but copies should not be provided to the journal. Only if specifically requested by the journal in exceptional circumstances (for example if a legal issue arises) the author must provide copies of the consents or evidence that such consents have been obtained. For more information, please review the Elsevier Policy on the Use of Images or Personal Information of Patients or other Individuals. Unless you have written permission from the patient (or, where applicable, the next of kin), the personal details of any patient included in any part of the article and in any supplementary materials (including all illustrations and videos) must be removed before submission.

**Conflict of interest**

All authors must disclose any financial and personal relationships with other people or organisations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. See also https://www.elsevier.com/conflictofinterest.

Please complete and upload the Conflict of Interest and Author Declaration form with your manuscript. Inclusion of this form is mandatory.

**Submission declaration and verification**

Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see 'Multiple, redundant or concurrent publication' for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service Crossref Similarity Check.

**Use of inclusive language**

Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Content should make no assumptions about the beliefs or commitments of any reader; contain nothing which might imply that one individual is superior to another on the grounds of age, gender, race, ethnicity, culture, sexual orientation, disability or health condition; and use inclusive language throughout. Authors should ensure that writing is free from bias, stereotypes, slang, reference to dominant culture and/or cultural assumptions. We advise to seek gender neutrality by using plural nouns ("clinicians, patients/clients") as default/wherever possible to avoid using "he, she," or "he/she." We recommend avoiding the use of descriptors that refer to personal attributes such as age, gender, race, ethnicity, culture, sexual orientation, disability or health condition unless they are relevant and valid. When coding terminology is used, we recommend to avoid offensive or exclusionary terms such as "master", "slave", "blacklist" and "whitelist". We suggest using alternatives that are more appropriate and (self-) explanatory such as "primary", "secondary", "blocklist" and "allowlist". These guidelines are meant as a point of reference to help identify appropriate language but are by no means exhaustive or definitive.

**Contributors**

Each author is required to declare his or her individual contribution to the article: all authors must have materially participated in the research and/or article preparation, so roles for all authors should be described. The statement that all authors have approved the final article should be true and included in the disclosure.
Changes to authorship
Authors are expected to consider carefully the list and order of authors before submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only before the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the corresponding author: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors after the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

Clinical trial results
In line with the position of the International Committee of Medical Journal Editors, the journal will not consider results posted in the same clinical trials registry in which primary registration resides to be prior publication if the results posted are presented in the form of a brief structured (less than 500 words) abstract or table. However, divulging results in other circumstances (e.g., investors’ meetings) is discouraged and may jeopardise consideration of the manuscript. Authors should fully disclose all posting in registries of results of the same or closely related work.

Reporting clinical trial
All randomised controlled trials submitted for publication should include a completed Consolidated Standards of Reporting Trials (CONSORT) flow chart. Please refer to the CONSORT statement website at http://www.consort-statement.org for more information and the STROBE statement for observational studies (see http://www.equator-network.org/). For human gene nomenclature, see the instructions at the back of the journal. This journal has adopted the proposal from the International Committee of Medical Journal Editors (ICMJE) which require, as a condition of consideration for publication of clinical trials, registration in a public trials registry. Trials must register at or before the onset of patient enrolment. The clinical trial registration number should be included at the end of the abstract of the article. For this purpose, a clinical trial is defined as any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects of health outcomes. Health-related interventions include any intervention used to modify a biomedical or health-related outcome (for example drugs, surgical procedures, devices, behavioural treatments, dietary interventions, and process-of-care changes). Health outcomes include any biomedical or health-related measures obtained in patients or participants, including pharmacokinetic measures and adverse events. Purely observational studies (those in which the assignment of the medical intervention is not at the discretion of the investigator) will not require registration. Further information can be found at http://www.icmje.org.

Copyright
Upon acceptance of an article, authors will be asked to complete a ‘Journal Publishing Agreement’ (for more information on this and copyright, see https://www.elsevier.com/copyright). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a ‘Journal Publishing Agreement’ form or a link to the online version of this agreement.

Author rights
As an author you (or your employer or institution) have certain rights to reuse your work. For more information on author rights please see https://www.elsevier.com/copyright.

Elsevier supports responsible sharing
Find out how you can share your research published in Elsevier journals.

Open access
Please visit our Open Access page for more information.

Elsevier Researcher Academy
Researcher Academy is a free e-learning platform designed to support early and mid-career researchers throughout their research journey. The "Learn" environment at Researcher Academy offers several interactive modules, webinars, downloadable guides and resources to guide you through the process of writing for research and going through peer review. Feel free to use these free resources to improve your submission and navigate the publication process with ease.
**Language and language services**
Please write your text in good English (American or British usage is accepted, but not a mixture of these). All accepted manuscripts will be edited prior to publication.

**Submission**
Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

**Submit your article**
Please submit your article via [https://www.editorialmanager.com/hemoncstem/default.aspx](https://www.editorialmanager.com/hemoncstem/default.aspx)

**Suggesting reviewers**
Please submit the names and institutional e-mail addresses of several potential reviewers.

You should not suggest reviewers who are colleagues, or who have co-authored or collaborated with you during the last three years. Editors do not invite reviewers who have potential competing interests with the authors. Further, in order to provide a broad and balanced assessment of the work, and ensure scientific rigor, please suggest diverse candidate reviewers who are located in different countries/regions from the author group. Also consider other diversity attributes e.g. gender, race and ethnicity, career stage, etc. Finally, you should not include existing members of the journal's editorial team, of whom the journal are already aware.

Note: the editor decides whether or not to invite your suggested reviewers.

**PREPARATION**

**Queries**
For questions about the editorial process (including the status of manuscripts under review) or for technical support on submissions, please visit our Support Center.

**Peer review**
This journal operates a double anonymized review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. Editors are not involved in decisions about papers which they have written themselves or have been written by family members or colleagues or which relate to products or services in which the editor has an interest. Any such submission is subject to all of the journal's usual procedures, with peer review handled independently of the relevant editor and their research groups. More information on types of peer review.

**Double anonymized review**
This journal uses double anonymized review, which means the identities of the authors are concealed from the reviewers, and vice versa. More information is available on our website. To facilitate this, please include the following separately:

- **Title page (with author details):** This should include the title, authors' names, affiliations, acknowledgements and any Declaration of Interest statement, and a complete address for the corresponding author including an e-mail address.
- **Anonymized manuscript (no author details):** The main body of the paper (including the references, figures, tables and any acknowledgements) should not include any identifying information, such as the authors' names or affiliations.

**Use of word processing software**
It is important that the file be saved in the native format of the word processor used. The text should be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. In particular, do not use the word processor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see
also the Guide to Publishing with Elsevier). Note that source files of figures, tables and text graphics will be required whether or not you embed your figures in the text. See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

**Article structure**

**Subdivision - numbered sections**
Divide your article into clearly defined and numbered sections. Subsections should be numbered 1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this numbering also for internal cross-referencing: do not just refer to 'the text'. Any subsection may be given a brief heading. Each heading should appear on its own separate line.

**Words limit**
Word count limits are 3500 words for original research reports, 2000 for brief communications and mini-reviews, and 750 for letters. The word count should include references listed at the end of the article.

**Introduction**
State the objectives of the work and provide adequate background to highlight the significance of your study, question asked, and hypothesis tested. Also, Avoid a detailed literature survey or a summary of the results.

**Material and methods**
Provide sufficient details to allow the work to be reproduced by an independent researcher. Methods that are already published should be summarized, and indicated by a reference. If quoting directly from a previously published method, use quotation marks and also cite the source. Any modifications to existing methods should also be described.

**Theory/calculation**
A Theory section should extend, not repeat, the background to the article already dealt with in the Introduction and lay the foundation for further work. In contrast, a Calculation section represents a practical development from a theoretical basis.

**Results**
The results section should always begin with text that reports the key results without interpretation, in an orderly and logical sequence, using both text and illustrative materials (Tables and Figures). Statistical analysis for your data should appear either in text (usually parenthetically), related Tables, or Figures (in the legend or in footnote under the Table or Figure).

**Discussion**
This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

**Conclusions**
The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

**Appendices**
If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix, Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc.

**Essential title page information**
- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
- **Author names and affiliations.** Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. You can add your name between parentheses in your own script behind the English transliteration. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
• **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. This responsibility includes answering any future queries about Methodology and Materials. **Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.**

• **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

**Abstract**
A concise and factual abstract is required which contains no more than 250 words. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself.

**Keywords**
Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

**Abbreviations**
Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.

**Acknowledgements**
Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

**Units**
Follow internationally accepted rules and conventions: use the international system of units (SI). If other units are mentioned, please give their equivalent in SI.

**Math formulae**
Please submit math equations as editable text and not as images. Present simple formulae in line with normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text).

**Footnotes**
Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors can build footnotes into the text, and this feature may be used. Otherwise, please indicate the position of footnotes in the text and list the footnotes themselves separately at the end of the article. Do not include footnotes in the Reference list.

**Artwork**

**Image manipulation**
Whilst it is accepted that authors sometimes need to manipulate images for clarity, manipulation for purposes of deception or fraud will be seen as scientific ethical abuse and will be dealt with accordingly. For graphical images, this journal is applying the following policy: no specific feature within an image may be enhanced, obscured, moved, removed, or introduced. Adjustments of brightness, contrast, or color balance are acceptable if and as long as they do not obscure or eliminate any information present in the original. Nonlinear adjustments (e.g. changes to gamma settings) must be disclosed in the figure legend.

**Electronic artwork**

**General points**
- Make sure you use uniform lettering and sizing of your original artwork.
- Embed the used fonts if the application provides that option.
• Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.
• Number the illustrations according to their sequence in the text.
• Use a logical naming convention for your artwork files.
• Provide captions to illustrations separately.
• Size the illustrations close to the desired dimensions of the published version.
• Submit each illustration as a separate file.
• Ensure that color images are accessible to all, including those with impaired color vision.

A detailed guide on electronic artwork is available.
You are urged to visit this site; some excerpts from the detailed information are given here.

Formats
If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native document format.
Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):
EPS (or PDF): Vector drawings, embed all used fonts.
TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.
TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.
TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi.

Please do not:
• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
• Supply files that are too low in resolution;
• Submit graphics that are disproportionately large for the content.

Figure captions
Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (not on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

Tables
Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules and shading in table cells.

Reference
List references in consecutive numerical order (the order of citation in the manuscript, and not alphabetically). Once a reference is cited, all subsequent citations should be to the original number. References to material on the Internet should include the date of access. Manuscripts with incorrectly formatted citations will be returned to the author for correction. The author is responsible for the accuracy and completeness of the references and for their correct textual citation. In-text reference numbers should be superscripted and placed after the period (not in parentheses), as at the end of this sentence.1 The reference style required by the journal will be applied to the published version by Elsevier.

Citation in text
Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.
Web references
As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

Data references
This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

References in a special issue
Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

Reference style
Text: Indicate references by number(s) in square brackets in line with the text. The actual authors can be referred to, but the reference number(s) must always be given.
List: Number the references (numbers in square brackets) in the list in the order in which they appear in the text.
Examples:
Reference to a journal publication:
Reference to a journal publication with an article number:
Reference to a book:
Reference to a chapter in an edited book:
Reference to a website:
Reference to a dataset:
Note shortened form for last page number. e.g., 51–9, and that for more than 6 authors the first 6 should be listed followed by 'et al.' For further details you are referred to 'Uniform Requirements for Manuscripts submitted to Biomedical Journals' (J Am Med Assoc 1997;277:927–34) (see also Samples of Formatted References).

Journal abbreviations source
Journal names should be abbreviated according to the List of Title Word Abbreviations.

Supplementary material
Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version.

AFTER ACCEPTANCE

Online proof correction
To ensure a fast publication process of the article, we kindly ask authors to provide us with their proof corrections within two days. Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to
MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors. If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

AUTHOR INQUIRIES
Visit the Elsevier Support Center to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch. You can also check the status of your submitted article or find out when your accepted article will be published.

Nomenclature for Human Genes
HEMONC_image.jpg

© Copyright 2018 Elsevier | https://www.elsevier.com